Active Biotech AB Interim Report January - June 2011

LUND, SWEDEN--(Marketwire - August 11, 2011) -

· Laquinimod - results of Phase III BRAVO trial reinforce unique profile of laquinimod for multiple sclerosis treatment

· TASQ - recruitment of patients for the Phase III trial ongoing

· TASQ - partnership agreement initiated with Ipsen

· ANYARA - Phase III trial continues according to plan

· 57-57 - preparation for the start of the SSC exploratory clinical trial in progress

· ISI - project is proceeding as planned

· RhuDex™ - preparations for continued clinical development in progress

· Net sales SEK 228.8 M (6.1)

· Operating profit SEK 70.6 M (loss: 102,4)

· Profit after tax SEK 77.7 M (loss: 108.3)

· Earnings per share for the period amounted to SEK 1.14 (loss: 1.67)

This report is also available at www.activebiotech.com

Active Biotech AB Interim Report January - June 2011: http://hugin.info/1002/R/1537777/469595.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1537777]